Manuel is an Investment Manager with >20 years of professional experience in Pharma R&D and BD&L. Manuel holds a PhD in Biomedical Science from the Biozentrum of the University of Basel in Switzerland. He joined Boehringer Ingelheim in 2011 as Lab Head in Cardio-Metabolic Diseases Research, focusing on research and new therapeutic concept identification in obesity and metabolic dysfunction-associated steatohepatits. Following his transition to BD&L in 2018, Manuel took on the role of Global Head of BD&L for Cardio-Renal-Metabolism & Retinal Health in 2019. He played a pivotal role in expanding the company's pipeline through the in-licensing of various preclinical programs. Manuel joined the BIVF on February 1, 2025.